Liraglutide Ameliorates Erectile Dysfunction
autophagy
diabetes mellitus
erectile dysfunction
liraglutide
oxidative stress
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2020
2020
Historique:
received:
29
04
2020
accepted:
30
07
2020
entrez:
9
9
2020
pubmed:
10
9
2020
medline:
10
9
2020
Statut:
epublish
Résumé
Erectile dysfunction (ED) occurs more frequently and causes a worse response to the first-line therapies in diabetics compared with nondiabetic men. Corpus cavernosum vascular dysfunction plays a pivotal role in the occurrence of diabetes mellitus ED (DMED). The aim of this study was to investigate the protective effects of glucagon-like peptide-1 (GLP-1) analog liraglutide on ED and explore the underlying mechanisms Type 1 diabetes was induced in rats by streptozotocin, and the apomorphine test was for screening the DMED model in diabetic rats. Then they were randomly treated with subcutaneous injections of liraglutide (0.3 mg/kg/12 h) for 4 weeks. Erectile function was assessed by cavernous nerve electrostimulation. The corpus cavernosum was used for further study. Administration of liraglutide did not significantly affect plasma glucose and body weights in diabetic rats, but improved erectile function, reduced levels of NADPH oxidases and ROS production, downregulated expression of Ras homolog gene family (RhoA) and Rho-associated protein kinase (ROCK) 2 in the DMED group dramatically. The liraglutide treatment promoted autophagy further and restored expression of GLP-1R in the DMED group. Besides, cultured CCSMCs with liraglutide exhibited a lower level of oxidative stress accompanied by inhibition of the RhoA/ROCK pathway and a higher level of autophagy compared with HG treatment. These beneficial effects of liraglutide effectively reversed by GLP-1R inhibitor. Liraglutide exerts protective effects on ED associated with the regulation of smooth muscle dysfunction, oxidative stress and autophagy, independently of a glucose- lowering effect. It provides new insight into the extrapancreatic actions of liraglutide and preclinical evidence for a potential treatment for DMED.
Sections du résumé
BACKGROUND
BACKGROUND
Erectile dysfunction (ED) occurs more frequently and causes a worse response to the first-line therapies in diabetics compared with nondiabetic men. Corpus cavernosum vascular dysfunction plays a pivotal role in the occurrence of diabetes mellitus ED (DMED). The aim of this study was to investigate the protective effects of glucagon-like peptide-1 (GLP-1) analog liraglutide on ED and explore the underlying mechanisms
METHODS
METHODS
Type 1 diabetes was induced in rats by streptozotocin, and the apomorphine test was for screening the DMED model in diabetic rats. Then they were randomly treated with subcutaneous injections of liraglutide (0.3 mg/kg/12 h) for 4 weeks. Erectile function was assessed by cavernous nerve electrostimulation. The corpus cavernosum was used for further study.
RESULTS
RESULTS
Administration of liraglutide did not significantly affect plasma glucose and body weights in diabetic rats, but improved erectile function, reduced levels of NADPH oxidases and ROS production, downregulated expression of Ras homolog gene family (RhoA) and Rho-associated protein kinase (ROCK) 2 in the DMED group dramatically. The liraglutide treatment promoted autophagy further and restored expression of GLP-1R in the DMED group. Besides, cultured CCSMCs with liraglutide exhibited a lower level of oxidative stress accompanied by inhibition of the RhoA/ROCK pathway and a higher level of autophagy compared with HG treatment. These beneficial effects of liraglutide effectively reversed by GLP-1R inhibitor.
CONCLUSION
CONCLUSIONS
Liraglutide exerts protective effects on ED associated with the regulation of smooth muscle dysfunction, oxidative stress and autophagy, independently of a glucose- lowering effect. It provides new insight into the extrapancreatic actions of liraglutide and preclinical evidence for a potential treatment for DMED.
Identifiants
pubmed: 32903510
doi: 10.3389/fphar.2020.01257
pmc: PMC7435068
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1257Informations de copyright
Copyright © 2020 Yuan, Ma, Gao, Wang, Li, Liu, Wang, Wang, Liu and Liu.
Références
J Urol. 2005 Jul;174(1):386-93
pubmed: 15947695
Sci Rep. 2017 Jul 13;7(1):5311
pubmed: 28706237
J Sex Med. 2019 Nov;16(11):1708-1720
pubmed: 31564534
Exp Clin Endocrinol Diabetes. 2015 Mar;123(3):141-58
pubmed: 25502583
Planta Med. 2016 Sep;82(14):1252-7
pubmed: 27552253
J Sex Med. 2009 Jan;6(1):91-106
pubmed: 19170840
Int Urol Nephrol. 2015 Jul;47(7):1105-15
pubmed: 25997594
Curr Med Chem. 2001 Jun;8(7):721-38
pubmed: 11375746
Andrology. 2013 May;1(3):487-94
pubmed: 23427186
Free Radic Res. 2013 Aug;47 Suppl 1:49-69
pubmed: 23822116
Int J Med Sci. 2017 Sep 19;14(12):1203-1212
pubmed: 29104476
Exp Ther Med. 2013 Aug;6(2):310-316
pubmed: 24137180
Atherosclerosis. 2015 May;240(1):250-9
pubmed: 25818251
Metabolism. 2012 Oct;61(10):1422-34
pubmed: 22554832
J Pharmacol Exp Ther. 2010 Apr;333(1):184-92
pubmed: 20093396
Br J Pharmacol. 2003 Sep;140(1):123-32
pubmed: 12967942
Neuropharmacology. 2018 Mar 15;131:316-325
pubmed: 29305122
Cardiovasc Diabetol. 2015 Feb 07;14:18
pubmed: 25855361
Mol Cell Endocrinol. 2017 Jun 15;448:98-107
pubmed: 28363742
Andrology. 2020 May;8(3):780-792
pubmed: 31955524
Diabetes Res Clin Pract. 2018 Apr;138:271-281
pubmed: 29496507
Physiol Rev. 2007 Jan;87(1):245-313
pubmed: 17237347
Clin Sci (Lond). 2018 Jan 11;132(1):111-125
pubmed: 29212786
J Sex Med. 2018 Sep;15(9):1246-1259
pubmed: 30224017
J Sex Med. 2013 Jun;10(6):1502-15
pubmed: 23566117
Oxid Med Cell Longev. 2018 Apr 19;2018:5396806
pubmed: 29849901
Andrology. 2015 Nov;3(6):1094-103
pubmed: 26447645
Cardiovasc Diabetol. 2013 Mar 27;12:51
pubmed: 23530857
Lancet. 2013 Jan 12;381(9861):153-65
pubmed: 23040455
EMBO J. 2007 Apr 4;26(7):1749-60
pubmed: 17347651
Asian J Androl. 2018 Mar-Apr;20(2):166-172
pubmed: 29111541
Atherosclerosis. 2017 Jun;261:44-51
pubmed: 28445811
Andrology. 2018 May;6(3):498-509
pubmed: 29603682
Curr Urol Rep. 2015 Dec;16(12):81
pubmed: 26480830
Nat Rev Urol. 2014 Nov;11(11):622-8
pubmed: 25311680
Diabetologia. 2010 Oct;53(10):2256-63
pubmed: 20593161
J Diabetes Complications. 2011 Mar-Apr;25(2):129-36
pubmed: 20462773
Cell Death Differ. 2015 Mar;22(3):377-88
pubmed: 25257172
Ann Intern Med. 2012 Nov 20;157(10):681-91
pubmed: 23165659
Biomed Pharmacother. 2019 May;113:108667
pubmed: 30852419
Structure. 2003 Dec;11(12):1595-607
pubmed: 14656443
Nat Rev Mol Cell Biol. 2007 Nov;8(11):931-7
pubmed: 17712358